拉帕蒂尼
曲妥珠单抗
医学
危险系数
肿瘤科
内科学
乳腺癌
置信区间
转移性乳腺癌
化疗
癌症
HER2阴性
卡培他滨
作者
Valentina Guarneri,Maria Vittoria Dieci,Gaia Griguolo,Federica Miglietta,Fabio Girardi,Giancarlo Bisagni,Daniele Generali,Katia Cagossi,Samanta Sarti,Antonio Frassoldati,Lorenzo Gianni,Luigi Cavanna,Graziella Pinotti,Antonino Musolino,Federico Piacentini,Saverio Cinieri,Aleix Prat,Pierfranco Conté
标识
DOI:10.1016/j.ejca.2021.05.018
摘要
The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.The Cher-LOB study randomised 121 patients with human epidermal growth factor receptor 2-positive, stage II-IIIA breast cancer. A specific protocol to collect recurrence-free survival (RFS) and overall survival (OS) data was designed. Tumour-infiltrating lymphocytes (TILs) and PAM50-intrinsic subtyping were evaluated at baseline.At 9-year median follow-up, a trend towards RFS improvement with lapatinib-trastuzumab over trastuzumab was observed (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.18-1.05). Combining treatment arms, pCR was significantly associated with both RFS (HR 0.12, 95% CI 0.03-0.49) and OS (HR 0.12, 95% CI 0.03-0.49). TILs were significantly associated with RFS (HR = 0.978 for each 1% increment). Luminal-A subtype was a significant and independent predictor of improved RFS as compared with other PAM50-based intrinsic subtypes at the multivariate analysis including the most relevant clinicopathologic variables (HR 0.29, 95% CI 0.09-0.94, p = 0.040).Cher-LOB trial survival analysis confirmed the prognostic role of pCR and TILs and showed a signal for a better outcome with lapatinib-trastuzumab over trastuzumab.NCT00429299.
科研通智能强力驱动
Strongly Powered by AbleSci AI